FSTX News and Press, F-star Therapeutics Inc Com From 02/09/23

F-star Therapeutics ( NASDAQ: FSTX ) rose 2.3% in premarket trading after announcing that it's extended the end date for its planned merger with invoX Pharma again as it continues to negotiate a possible mitigation agreement with CFIUS. The end date is being extended from Fri...

F-star Therapeutics ( NASDAQ: FSTX ) rose 6% as buyer Sino Pharmaceutical ( OTCPK:SBHMY ) canceled a planned Shanghai stock exchange listing. The termination of the planned listing on the exchange for Sino Pharmaceutical comes as the company's planned acquisition of F-star ( ...

F-star Therapeutics ( NASDAQ: FSTX ) is up 18% in premarket trading after announcing that it is extending the end date of its planned merger with invoX Pharma. The extension is to further hammer out negotiations with the Committee on Foreign Investment in the United States om...

Summary FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns. If the deal closes, the stock should rise 30%; if it fails, FSTX still has very valuable assets. The only r...

LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statemen...

F-star Therapeutics plunged 20% on a report that the buyer of the company doesn't expect a favorable outcome from the  Committee on Foreign Investment or CFIUS review of the deal. invoX Pharma, the unit of China’s Sino Biopharmaceutical that's is buying F-star ( NASDAQ:...

Summary Merger arbitrage spreads are wide. There are plenty of opportunities with spreads of up to 81%. This is a detailed review of the most interesting transactions in the space. Merger arbitrage is an event-driven investment strategy of betting on a successful acquisiti...

Following a ~40% decline in the previous session, shares of the U.K.-based biotech F-star Therapeutics ( NASDAQ: FSTX ) surged ~43% on Friday as investors reacted to an announcement on an extension to close the company's merger agreement with invoX Pharma. In June, U.K.-based invo...

U.K.-based biotech F-star Therapeutics ( NASDAQ: FSTX ) shed ~37% pre-market Thursday in reaction to a filing indicating that regulatory watchdog The Committee on Foreign Investment (CFIUS) issued an interim order blocking its planned sale to Sino-Biopharma ( OTCPK:SBHMY ) ( OTC...

Summary In my opinion, there is value in lowering portfolio volatility over the long term. You don't need to invest solely in assets with lower volatility to bring portfolio volatility down. Asset classes, factors and even certain stocks can interact with a portfolio in highly benef...